Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Solid Tumor, Adult 1Sarcoma, Synovial 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphatic Metastasis 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Dermatofibrosarcoma 1

Interventions

Specimen Handling 4Gemcitabine 3Doxorubicin 3liposomal doxorubicin 2Trabectedin 2Magnetic Resonance Spectroscopy 2Dacarbazine 2Biopsy 2toripalimab 1regorafenib 1peposertib 1cemiplimab 1anlotinib 1abemaciclib 1X-Rays 1Tretinoin 1Tissue Banks 1Tablets 1Surgical Procedures, Operative 1Standard of Care 1Rosuvastatin Calcium 1Radiotherapy 1Quality of Life 1Nivolumab 1Neoadjuvant Therapy 1Midazolam 1Injections 1Immunoglobulin G 1Ifosfamide 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leiomyosarcoma × peposertib × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡